Skip to main content
BioMed Research International logoLink to BioMed Research International
. 2025 Aug 25;2025:9793841. doi: 10.1155/bmri/9793841

Corrigendum to “Exendin-4 Attenuates Hepatic Steatosis by Promoting the Autophagy-Lysosomal Pathway”

PMCID: PMC12401594  PMID: 40900906

H.-H. Yu, H.-C. Wang, M.-C. Hsieh, M.-C. Lee, B.-C. Su, and Y.-S. Shan, “Exendin-4 Attenuates Hepatic Steatosis by Promoting the Autophagy-Lysosomal Pathway,” BioMed Research International 2022, (2022): 4246086, https://doi.org/10.1155/2022/4246086.

In the article, there is an error in Figure 2e, which was mistakenly duplicated from Figure 2d in the production process. Additionally, the Figure 2 legend contains errors. The correct Figure 2 and its accompanying legend is shown below:

Figure 1.

Figure 1

Exendin-4 attenuates unsaturated fatty acid–induced steatosis. (a) HepG2 cells were transfected with shLuc (nontargeting shRNA) or shLC3-1/shLC3-2 for 48 h. Subsequently, the cells were treated with OA (250 μM) or PA (250 μM) for 24 h. The cells were then treated with or without Exendin-4 (200 nM) for another 24 h. Oil Red O staining was performed. (b, c) Quantification of Oil Red O signals. (d, e) Cells were treated as described in (a); cell lysates were collected and immunoblotted with the indicated antibodies. All experiments were repeated three times with similar results.

We apologize for this error.


Articles from BioMed Research International are provided here courtesy of Wiley

RESOURCES